PDE5 inhibitors / Cialis / Viagra

ID: pde5_inhibitors

Aliases: PDE5 inhibitors, phosphodiesterase type 5 inhibitors, Cialis, Viagra, Levitra, Stendra, tadalafil, sildenafil, vardenafil, avanafil, ED drugs

Type: compound_family

Route/form: oral prescription tablets in ED/BPH contexts; pulmonary hypertension products and routes differ by drug

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_physiology, label, meta_analysis, systematic_review

Linked sources: 9

Broad outcomes: Cardiovascular / lipids / blood pressure, Hormones / fertility / sexual health, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• PDE5 inhibition
• NO/cGMP signaling preservation
• corpus cavernosum smooth-muscle relaxation
• pulmonary and systemic vascular tone modulation

Optimization domains

• erectile
• sexual
• libido
• vascular
• endothelial
• blood pressure
• cardiovascular
• exercise performance
• pump
• pulmonary hypertension
• nitric oxide

Research basis

• The class has strong approved-drug and meta-analytic human evidence for erectile function, which is the primary reason Cialis/Viagra-type compounds belong here.
• The optimization rationale is not that PDE5 inhibitors create nitric oxide; they preserve downstream cGMP signaling after NO release, which plausibly intersects with erection quality, endothelial function, pulmonary vascular physiology, and workout pump perception.
• Exercise-performance evidence is narrow: sildenafil has some hypoxia/altitude physiology support, while systematic reviews show inconsistent benefit and little reason to expect a robust normoxic performance effect.

Limits, risks, and missing evidence

• PDE5 inhibitors are prescription vasodilatory drugs, not generic preworkouts; nitrates, riociguat/GC stimulators, alpha-blockers, antihypertensives, alcohol, CYP3A4 interactions, cardiovascular status, and ocular/hearing adverse events matter.
• Long-term cardiovascular-outcome meta-analyses are hypothesis-generating and partly observational; they should not be read as proof that healthy users reduce mortality by taking PDE5 inhibitors.
• Gym pump, vascularity, and recovery claims are mechanistically plausible but much weaker than ED evidence and should be kept separate from disease-label efficacy.

Risk flags

• prescription only
• nitrate contraindication
• blood pressure interactions
• ocular hearing warnings
• performance claims weak

Linked papers, labels, and reviews

1. Tadalafil tablet, film coated - Prescribing Information
   label / dailymed_tadalafil_label
   DailyMed label for oral tadalafil, including ED/BPH dosing, nitrate/riociguat contraindications, alpha-blocker/antihypertensive cautions, and common adverse effects.
2. VIAGRA (sildenafil citrate) tablets - Prescribing Information
   label / dailymed_viagra_label
   DailyMed label for oral sildenafil/Viagra, including ED dosing, nitrate/riociguat contraindications, CYP3A4 interaction cautions, and adverse-effect profile.
3. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis
   meta_analysis / pubmed_pde5_ed_meta_2009
   Broad ED systematic review/meta-analysis covering sildenafil, tadalafil, vardenafil, and hormonal comparators.
4. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis
   meta_analysis / pubmed_pde5_ed_network_meta_2020
   Network meta-analysis comparing PDE5 inhibitors for ED efficacy and adverse effects; useful class-level efficacy/safety context.
5. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis
   meta_analysis / pubmed_tadalafil_sildenafil_meta_2017
   Head-to-head tadalafil versus sildenafil systematic review/meta-analysis; useful for duration/tolerability preference framing without implying one is universally superior.
6. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia
   human_physiology / pubmed_sildenafil_hypoxia_performance_2006
   Healthy-human physiology study supporting the narrow altitude/hypoxia performance rationale and the lack of normoxia performance effect.
7. Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review
   systematic_review / pubmed_sildenafil_hypoxia_review_2019
   Systematic review showing the hypoxia-performance signal is inconsistent; useful against gym-performance overclaiming.
8. Efficacy of Sildenafil on healthy humans in high-altitude hypoxia at rest and during exercise: A meta-analysis
   meta_analysis / pubmed_sildenafil_hypoxia_meta_2024
   Recent meta-analysis on sildenafil in healthy humans exposed to high-altitude hypoxia; supports route-specific and environment-specific performance context.
9. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis
   meta_analysis / pubmed_pde5_cvd_outcomes_meta_2024
   Long-term cardiovascular-outcome meta-analysis; mostly observational/heterogeneous evidence, useful as hypothesis-generating rather than proof of mortality benefit.